tiprankstipranks
Moleculin Biotech (MBRX)
NASDAQ:MBRX

Moleculin Biotech (MBRX) AI Stock Analysis

Compare
1,500 Followers

Top Page

MB

Moleculin Biotech

(NASDAQ:MBRX)

32Underperform
Moleculin Biotech faces significant financial challenges typical of early-stage biotech firms, with no revenue and increasing losses. The stock is under bearish technical indicators, reflecting low investor confidence. However, positive developments in clinical trials and a solid financial runway offer potential upside if milestones are met. The overall risk remains high due to financial instability and the high costs associated with ongoing trials.
Positive Factors
Clinical Trial Progress
The planned Phase 3 'MIRACLE' trial is based on positive Phase 1b/2 results, which showed promising complete remission rates in patients with previous treatment lines, bolstering confidence in Annamycin's potential.
Drug Characteristics
Annamycin is differentiated from other anthracyclines for not showing cumulative cardiotoxicity, which limits long-term use of other anthracyclines.
Regulatory Approval
Annamycin currently has Fast Track and Orphan Drug Designation from the FDA for the treatment of R/R AML, increasing potential to accelerate its timeline for approval.
Negative Factors
Commercial Timelines
The commercial timelines for Annamycin in acute myeloid leukemia have been pushed out to 2029 due to extended trial timelines.
Financial Challenges
The company's cash reserves are low with high quarterly cash burn, necessitating immediate capital raising efforts.
Stock Dilution
The company is seeking to raise capital through the sale of common stock and warrants, which could lead to significant share dilution and affect the company's ability to operate.

Moleculin Biotech (MBRX) vs. S&P 500 (SPY)

Moleculin Biotech Business Overview & Revenue Model

Company DescriptionMoleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
How the Company Makes MoneyMoleculin Biotech primarily makes money through the development and potential commercialization of its oncology drug candidates. The company seeks to generate revenue by advancing its drug candidates through clinical trials and securing regulatory approvals. Revenue streams may include licensing agreements, collaborations with larger pharmaceutical companies, and potential sales of approved drugs. Additionally, Moleculin may receive milestone payments and royalties from partners involved in the commercialization of its drug candidates. The company's financial success heavily relies on its ability to successfully demonstrate the efficacy and safety of its drug candidates in clinical trials and to navigate the regulatory landscape for drug approvals.

Moleculin Biotech Financial Statement Overview

Summary
Moleculin Biotech is in a challenging financial position typical for early-stage biotech firms. The absence of revenue and increasing losses highlight the high-risk nature of its operations. Despite low debt levels, the declining equity and assets raise concerns about long-term sustainability, with continuous reliance on external funding.
Income Statement
10
Very Negative
Moleculin Biotech has consistently reported zero revenue over the years, reflecting its pre-commercial stage typical in the biotech industry. The net income has been negative, with increasing losses each year, indicating growing expenses without revenue generation. This suggests a high-risk profile in terms of profitability and revenue generation.
Balance Sheet
25
Negative
The company's debt-to-equity ratio remains low due to minimal debt levels, which is positive for financial stability. However, the equity has been declining over the years, reflecting continuous operational losses. The equity ratio suggests a relatively moderate reliance on equity financing, but the declining trend in total assets highlights potential liquidity concerns.
Cash Flow
15
Very Negative
Moleculin Biotech has been consistently generating negative free cash flow, with no signs of improvement, reflecting its high cash burn rate common in biotech firms. The operating cash flow to net income ratio is high due to substantial operating losses. Financing cash flows have been positive, indicating reliance on external funding for operations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-127.00K-222.00K-260.00K-285.00K
EBIT
-26.64M-29.63M-30.64M-22.97M-19.74M
EBITDA
-26.52M-29.50M-30.51M-22.80M-19.54M
Net Income Common Stockholders
-21.76M-29.77M-27.41M-8.86M-15.00M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.28M23.55M43.15M70.90M15.17M
Total Assets
16.93M38.22M57.42M84.09M29.03M
Total Debt
478.00K574.00K451.00K159.00K277.00K
Net Debt
-3.80M-22.98M-42.69M-70.74M-14.90M
Total Liabilities
10.95M12.14M5.23M5.10M11.27M
Stockholders Equity
5.98M26.07M52.19M78.99M17.76M
Cash FlowFree Cash Flow
-23.88M-24.23M-27.71M-18.97M-18.15M
Operating Cash Flow
-23.86M-24.10M-27.64M-18.95M-17.77M
Investing Cash Flow
-13.00K-124.00K-67.00K-19.00K-374.00K
Financing Cash Flow
4.63M4.65M-23.00K74.72M22.55M

Moleculin Biotech Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.87
Price Trends
50DMA
1.21
Negative
100DMA
1.71
Negative
200DMA
2.28
Negative
Market Momentum
MACD
-0.07
Positive
RSI
40.08
Neutral
STOCH
12.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBRX, the sentiment is Negative. The current price of 0.87 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.21, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 40.08 is Neutral, neither overbought nor oversold. The STOCH value of 12.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBRX.

Moleculin Biotech Risk Analysis

Moleculin Biotech disclosed 58 risk factors in its most recent earnings report. Moleculin Biotech reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Moleculin Biotech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
46
Neutral
$248.02M-33.88%-22.66%
42
Neutral
$9.64M-52.85%8.99%
36
Underperform
$47.69M-807.39%-80.98%62.27%
36
Underperform
$96.01M-424.44%51.02%
32
Underperform
$12.27M-135.80%52.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MBRX
Moleculin Biotech
0.87
-4.33
-83.27%
CYCC
Cyclacel Pharmaceuticals
0.23
-1.87
-89.05%
MNOV
Medicinova
1.34
-0.15
-10.07%
IMUX
Immunic
1.05
-0.23
-17.97%
CTXR
Citius Pharmaceuticals
1.03
-23.95
-95.88%
AVIR
Atea Pharmaceuticals
2.90
-0.91
-23.88%

Moleculin Biotech Earnings Call Summary

Earnings Call Date: Mar 24, 2025 | % Change Since: -20.18% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for Moleculin Biotech, emphasizing the promising data from the Phase 2 trial of Annamycin and the initiation of the MIRACLE Phase 3 trial. The company's solid financial position and clear focus on future milestones are also highlighted. However, there are challenges related to delayed enrollment in the US and the high cost of the Phase 3 trial.
Highlights
Launch of MIRACLE Phase 3 Trial
Moleculin Biotech has launched the MIRACLE Phase 3 pivotal trial for Annamycin in combination with Cytarabine for the second line treatment of relapsed and refractory AML patients. Regulatory and ethics approval has been obtained in the first European country, and patient screening has begun.
Positive Phase 2 Data for Annamycin
Phase 2 data shows Annamycin achieving a 50% complete remission rate in second-line AML patients, with a median progression-free survival of nine months and overall survival at 11 months. The drug has shown better performance than any existing therapies with a comparable CR rate.
Strong Financial Position
Moleculin Biotech has raised approximately $9 million in February 2025, leading to a combined cash balance of $13 million, extending runway into the third quarter of 2025.
Potential Game-Changer for AML Treatment
Annamycin has shown no drug-related cardiotoxicity and overcomes resistance to Venetoclax in AML. It is recognized as potentially the first non-cardiotoxic anthracycline, with experts acknowledging its significance.
Pipeline and Future Milestones
Moleculin is planning to publicly release data from MB107 in April and hopes to develop a pivotal investigator-initiated trial in Europe later in 2025. The company is focused on operational execution and meeting its milestones.
Lowlights
Delayed US Enrollment in MIRACLE Trial
The US is expected to be one of the last countries to begin enrolling patients in the MIRACLE Phase 3 trial due to longer approval processes involving institutional review boards and hospital contract negotiations.
High Cost of Phase 3 Trial
The expected cost of the Phase 3 trial is upwards of $60 million to $70 million, with anticipated cash burn increasing to $7 million or $8 million per quarter in 2026.
Company Guidance
During the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call, the company provided detailed guidance on the progress of their MIRACLE Phase 3 pivotal trial for Annamycin in combination with Cytarabine for relapsed and refractory AML patients. The trial is set across 25 sites in the US, Europe, and the Middle East, with patient screening underway and treatment expected to begin soon. The trial includes two parts, with multiple unblindings of data planned to enhance visibility for stakeholders. The first unblinding will occur after 45 subjects, expected by the end of 2025, and a second between 75 and 90 subjects in the first half of 2026. Annamycin's previous Phase 2 data showed promising results with an 11-month overall survival and a 50% complete remission rate, surpassing existing therapies. Moleculin also highlighted financial metrics, reporting cash on hand and recent capital raises totaling approximately $13 million, which will support operations into Q3 2025. The company aims to keep its cash burn at $5 million per quarter, increasing to $7-8 million as they progress into 2026.

Moleculin Biotech Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing
Positive
Apr 1, 2025

On April 1, 2025, Moleculin Biotech announced the commencement of dosing for the first patient in its Phase 3 MIRACLE trial, which evaluates Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML). This trial marks a significant milestone for the company and the AML community, with initial data expected in the second half of 2025. The trial’s adaptive design and global scope aim to accelerate Annamycin’s development towards approval, potentially impacting Moleculin’s market positioning and providing valuable insights for stakeholders.

Regulatory Filings and Compliance
Moleculin Biotech Shares Corporate Presentation Update
Neutral
Mar 24, 2025

On March 24, 2025, Moleculin Biotech, Inc. utilized a corporate presentation for its website, which was detailed in a Current Report on Form 8-K. The presentation, noted as Exhibit 99.1, was shared for informational purposes and not intended for filing under the Securities Exchange Act of 1934 or the Securities Act of 1933.

Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Gets FDA Nod for Phase 3 Trial
Positive
Feb 13, 2025

On February 13, 2025, Moleculin Biotech announced receiving FDA feedback that allows a reduced size for its Phase 3 trial protocol evaluating Annamycin combined with Cytarabine for treating relapsed or refractory AML. This trial, named MIRACLE, will be conducted globally, including in the US, Europe, and the Middle East, and aims to accelerate the approval timeline for this potentially groundbreaking non-cardiotoxic anthracycline. The feedback enables quicker site openings and recruitment, with implications for significantly impacting AML treatment and eliminating cardiotoxic risks in cancer therapies.

Product-Related AnnouncementsBusiness Operations and Strategy
Moleculin Biotech Gains European Approval for Phase 3 Trial
Positive
Feb 11, 2025

On February 11, 2025, Moleculin Biotech announced receiving regulatory approval in Europe to start recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia. The trial will include sites in the US, Europe, and the Middle East. The announcement signifies a crucial step in advancing their pivotal clinical trial, aiming for unblinded preliminary data from the first 45 subjects in the second half of 2025, potentially enhancing their market position in cancer therapeutics.

Product-Related AnnouncementsBusiness Operations and Strategy
Moleculin Biotech Launches MIRACLE Study for AML
Positive
Jan 27, 2025

On January 27, 2025, Moleculin Biotech announced the launch of its MIRACLE pivotal study for second line relapsed/refractory acute myeloid leukemia (AML), marking a significant milestone in its drug development efforts. The company has made substantial progress in preparing for this global registration trial, including selecting over 25 clinical sites and expecting to activate over 70, with the first patient anticipated to be treated within the first quarter. The trial aims to complete the 90-patient Part A by early 2026. Moleculin’s drug Annamycin shows promising preliminary results, outpacing competitors, and is generating increased interest from potential partners, reflecting its potential impact on the AML treatment landscape.

Product-Related AnnouncementsBusiness Operations and Strategy
Moleculin Biotech Shares Updates on MIRACLE Trial
Positive
Jan 27, 2025

On January 27, 2025, Moleculin Biotech announced that its CEO, Walter Klemp, participated in a Virtual Investor ‘What This Means’ segment. During the event, Klemp shared updates on the MIRACLE trial, a Phase 3 study evaluating Annamycin for treating relapsed or refractory acute myeloid leukemia. This trial is a significant step for Moleculin as it expands globally, with sites in the US, Europe, and the Middle East, and reflects advancements in AML treatment. Moleculin’s progress in developing Annamycin and other drug candidates could enhance its position in the pharmaceutical industry, with potential implications for regulatory approval and stakeholder investment.

Business Operations and Strategy
Moleculin Biotech Shares Corporate Presentation Update
Neutral
Jan 8, 2025

Moleculin Biotech, Inc. announced the use of a corporate presentation as part of its communication strategy, which is now available on their website. This presentation is being shared for informational purposes and will not be filed under the Securities Exchange Act, which may impact how stakeholders and investors perceive the company’s communications.

Product-Related AnnouncementsBusiness Operations and Strategy
Moleculin Biotech Advances Annamycin to Phase 3 Trial
Positive
Jan 8, 2025

Moleculin Biotech announced significant progress in the development of its drug Annamycin, particularly for relapsed or refractory acute myeloid leukemia (AML). The company has received approval for a pivotal Phase 3 trial, with initial data indicating Annamycin’s potential superiority over existing therapies. The accelerated trial timelines and promising preliminary results could enhance Moleculin’s market position and provide substantial value to stakeholders.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.